Navigation Links
OncoMed Pharmaceuticals Completes Series B Financing
Date:11/4/2008

Lead Cancer Stem Cell Product Candidate Enters Clinical Trials

REDWOOD CITY, Calif., Nov. 4 /PRNewswire/ -- OncoMed Pharmaceuticals, a clinical-stage company developing novel antibody therapeutics that target cancer stem cells, today announced the successful completion of the final tranche of its Series B financing round, raising $93 million. This tranche brings the total Series B financing to $154 million. New investor Nomura Phase4 Ventures participated in the financing along with existing OncoMed investors.

Proceeds from the financing will support the advancement of OncoMed's proprietary cancer stem cell antibody programs, including lead compound OMP- 21M18 and a second antibody, through Phase II clinical trials. OncoMed investors include top-tier venture capital firms US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Adams Street Partners, DeNovo Ventures and Bay Partners, as well as its strategic collaborator, GlaxoSmithKline.

"We are pleased to have completed this financing and to add Nomura Phase4 Ventures to our highly-regarded list of investors," said Paul Hastings, OncoMed's President and Chief Executive Officer. "These funds provide the company with multiple years of operating cash, and will enable OncoMed to take two cancer stem cell antibody therapeutics through Phase II clinical trials, as well as to expand our monoclonal antibody pipeline."

"Cancer stem cells appear to be a promising target for cancer treatment and OncoMed is a leader in the discovery of anti-cancer stem cell antibodies. We are pleased to support their development efforts through this investment," said Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures.

OMP-21M18 Enters Human Clinical Trials

OncoMed's lead anti-cancer stem cell antibody, OMP-21M18, entered human clinical studies earlier this year with the initiation of a Phase I trial in patients with advanced solid tumors. OMP-21M18 targets a major cancer stem cell pathway, and is a part of OncoMed's collaboration with GlaxoSmithKline. The Phase I clinical trial is designed to evaluate the safety of escalating doses of OMP-21M18 in patients with solid tumors who have received previous treatment. Pharmacokinetics and initial indications of efficacy will also be assessed. OMP-21M18 is the first anti-cancer stem cell antibody against this novel target critical to cancer stem cells growth and development.

Cancer stem cells, a small subset of cells found in tumors, have the capacity to self-renew and differentiate, initiate and drive tumor growth, recurrence and metastasis. Also termed "tumor-initiating cells", these cells were discovered by OncoMed's scientific founders in breast cancer and have subsequently been identified in many other types of solid tumors including: colon, head and neck, lung, prostate, glioblastoma and pancreatic. Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy. OncoMed's strategy is to improve cancer treatment by specifically targeting the key biologic pathways critical for the activity and survival of cancer stem cells. OncoMed's antibodies targeting cancer stem cell proteins have the potential to be developed against a range of solid tumor types such as pancreatic, breast, colorectal and lung cancers.

In conjunction with the financing, Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures, will join OncoMed's Board of Directors.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers. OncoMed's lead candidate, OMP-21M18 is currently in Phase I clinical trials. Privately-held, OncoMed's investors include: Nomura Phase4 Ventures, US Venture Partners, Latterell Venture Partners, Morgenthaler Ventures, The Vertical Group, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline. Additional information can be found at the company's website: http://www.oncomed.com.


'/>"/>
SOURCE OncoMed Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
2. Genesis Pharmaceuticals Launches New Corporate Website
3. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
6. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
7. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
11. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):